Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer.
about
Role of the tumor microenvironment in mature B-cell lymphoid malignanciesImmunotherapy in Chronic Lymphocytic Leukaemia (CLL)Impaired T-Cell Function in B-Cell Lymphoma: A Direct Consequence of Events at the Immunological Synapse?Modulation of antigen-specific T-cells as immune therapy for chronic infectious diseases and cancerTargeting neoplastic B cells and harnessing microenvironment: the "double face" of ibrutinib and idelalisibCatching up with solid tumor oncology: what is the evidence for a prognostic role of programmed cell death-ligand 1/programmed cell death-1 expression in B-cell lymphomas?Lymphoma: immune evasion strategiesCAR therapy: the CD19 paradigmChronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide.Phase I-II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints.T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers.Using Murine Models to Investigate Tumor-Lymphoid Interactions: Spotlight on Chronic Lymphocytic Leukemia and Angioimmunoblastic T-Cell Lymphoma.Immune checkpoint blockade for hematologic malignancies: a reviewModern treatment in chronic lymphocytic leukemia: impact on survival and efficacy in high-risk subgroupsAdvances in treating chronic lymphocytic leukemiaCutaneous T-Cell Lymphoma: A Review with a Focus on Targeted Agents.Transplantation in chronic lymphocytic leukemia: does it still matter in the era of novel targeted therapies?PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemiaMechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Eµ-TCL1 CLL mouse model.Microenvironment abnormalities and lymphomagenesis: Immunological aspects.Initial treatment of CLL: integrating biology and functional status.Idelalisib and caffeine reduce suppression of T cell responses mediated by activated chronic lymphocytic leukemia cells.Expression and function of the TL1A/DR3 axis in chronic lymphocytic leukemia.The role of B7 family molecules in hematologic malignancyIbrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemiaT cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production.Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia.Improving therapy of chronic lymphocytic leukemia with chimeric antigen receptor T cellsEliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL.Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications.Chronic lymphocytic leukemia cells diversify and differentiate in vivo via a nonclassical Th1-dependent, Bcl-6-deficient processThe PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia.Follicular lymphoma cells induce changes in T-cell gene expression and function: potential impact on survival and risk of transformation.Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune CharacteristicsPD-1 expression on the surface of peripheral blood CD4(+) T cell and its association with the prognosis of patients with diffuse large B-cell lymphoma.Phenotypic alteration of CD8+ T cells in chronic lymphocytic leukemia is associated with epigenetic reprogramming.Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT.New Pharmacotherapies in Chronic Lymphocytic Leukemia.NK cell function is markedly impaired in patients with chronic lymphocytic leukaemia but is preserved in patients with small lymphocytic lymphoma.Lenalidomide in lymphomas and chronic lymphocytic leukemia.
P2860
Q26748775-E485FEA3-CD70-4FEE-8442-1A7B965B8F21Q26768154-F46491E9-AF5A-430C-AABA-F92F8CA3ADD5Q27003955-49FDD0E6-72BD-420E-8D12-BDC3BDC33157Q27022761-7FF20FFB-E11E-47C4-81A8-C767629FC4FAQ27025812-CF7EE635-E543-4682-9D34-17878E5BE7D5Q28076071-7E704BB1-3100-4771-A270-7ADBE58EE2B2Q28080705-F1E538D7-D1E4-4123-B2DB-B503BD7AC399Q28081642-5A1DE5CA-E87C-42A5-836E-90DEDFFD640BQ30538420-CE13E1E8-06FA-4DFC-AE70-ED166288B0ECQ33436535-46DCCF2E-3AB6-48D9-BC11-2A917A4DC0EAQ33573774-12E61651-E6AA-4F59-A95C-2F2559380F95Q33621881-AF440A73-1E8F-451C-B07D-42A5825A42C5Q33645590-4849BC59-14B0-4EFC-9A28-F1A73FF58DB1Q33913537-7391B940-52E0-422E-9EB2-34945ECB1652Q34019917-C9253DAF-820F-43FA-A5A0-358FA2A72ACBQ34516083-8AEF37BC-EB46-4A4A-83B9-D374EC20A2C9Q34625543-81A08A95-9D65-4611-9768-6BA1AE9386C0Q35836860-17B3BCD6-9CDA-4D31-8BF6-AB3108C23FE1Q35836864-8F3E03DB-57C6-4BB2-932C-BC5E192D2E6BQ36118020-683CD561-8E7A-432F-A330-2648249B38B3Q36219647-8C6DDDB3-23C3-4B17-8AA2-54DBD7E96F78Q36296595-AD0A9E90-E36C-4AB6-899A-C0EDD16BDC77Q36544769-A60468CE-11FA-4A16-B2A5-DAF261E57579Q36584814-56215D2C-1360-42DA-B1B4-317C7ABF155FQ36651344-0BD92259-FA95-46F0-B319-08F0DA74A151Q36654128-563EA015-4042-415C-A70F-13D14771F16AQ36715966-E5AFBE3F-939E-49CA-B973-9F12D952B82DQ36777093-C11D4801-561F-4E54-BA30-2989F8E1107CQ36788133-A8F3D741-6791-4292-B2C0-1A80A7B1EBD2Q36862781-1B9645B9-DA16-4E78-BBC6-7F2B789B4A7AQ36867167-681E5BB2-1543-4130-BEB2-E65E024A185CQ36892616-936B0FD6-92E7-47A2-A258-1543824EA72CQ37004749-4171DAEA-EF97-4B43-8233-F836C885DD94Q37427107-D8167105-CBAE-451E-B460-D9370487001CQ37429917-79423443-58FD-4D56-8D16-074839CB0C67Q37457945-78E5C612-716A-47CC-84AE-E95FE54C5821Q37528067-A382B765-829B-4695-AF45-65C92C731ED2Q37605306-3E136D4A-5C6A-4CFF-96D2-25B0E11A9891Q37708827-D26308E6-6487-4C20-99B3-044CF1A8B9DBQ38077277-58353081-AF1B-4B6B-BE37-E51ED2F40F30
P2860
Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Multiple inhibitory ligands in ...... ion mechanism in human cancer.
@ast
Multiple inhibitory ligands in ...... ion mechanism in human cancer.
@en
type
label
Multiple inhibitory ligands in ...... ion mechanism in human cancer.
@ast
Multiple inhibitory ligands in ...... ion mechanism in human cancer.
@en
prefLabel
Multiple inhibitory ligands in ...... ion mechanism in human cancer.
@ast
Multiple inhibitory ligands in ...... ion mechanism in human cancer.
@en
P2093
P2860
P1433
P1476
Multiple inhibitory ligands in ...... ion mechanism in human cancer.
@en
P2093
Alan G Ramsay
Andrew J Clear
John G Gribben
Rewas Fatah
P2860
P304
P356
10.1182/BLOOD-2012-02-411678
P407
P577
2012-04-30T00:00:00Z